News Center

位置：

Honors Announcement

Group News

Media Reports

Moving Toward the “New” and Empowering with “Intelligence”: Creating Ultimate Excellence in the Pharmaceutical Industry—Shijiazhuang No. 4 Pharmaceutical Group Selected as a Case Study in the “Industrial Strengthening” Corporate History and Chronicle

Category:

Honors Announcement

发布时间：2024-09-19

【概要描述】 Recently, Shijiazhuang Sihua Pharmaceutical Group organized the compilation and submission of the practice case titled “Moving Toward the ‘New’ and Empowering with ‘Intelligence’: Creating the Ultimate in Pharmaceutical Excellence.” Grounded in the company’s commitment to technological self-reliance and innovative development, this case delves into how the enterprise has accelerated the cultivation of new productive forces—particularly through digital transformation and the commercialization of scientific and technological achievements—while driving product and service innovation. It systematically and clearly showcases the new accomplishments and outcomes achieved as the company advances the integrated and synergistic development of high-end, intelligent, and green operations, and has thus been successfully selected as a case study in the second batch of the “Industrial Strengthening” corporate history and chronicle series by the Industrial Culture Development Center of the Ministry of Industry and Information Technology.

Moving Toward the “New” and Empowering with “Intelligence”: Creating Ultimate Excellence in the Pharmaceutical Industry—Shijiazhuang No. 4 Pharmaceutical Group Selected as a Case Study in the “Industrial Strengthening” Corporate History and Chronicle

Recently, Shijiazhuang Sihua Pharmaceutical Group organized the compilation and submission of the practice case titled “Moving Toward the ‘New’ and Empowering with ‘Intelligence’: Creating the Ultimate in Pharmaceutical Excellence.” Grounded in the company’s commitment to technological self-reliance and innovative development, this case delves into how the enterprise has accelerated the cultivation of new-quality productive forces—particularly through digital transformation and the commercialization of scientific and technological achievements—and highlights exemplary instances of product and service innovation. The case systematically and clearly showcases the new accomplishments and outcomes achieved as the company advances the integrated and synergistic development of high-end, intelligent, and green operations, and has thus been successfully selected as a second-batch “Industrial Strengthening” corporate history and chronicle case by the Industrial Culture Development Center of the Ministry of Industry and Information Technology.

Over the past 76 years of relentless progress, Shijiazhuang No.4 Pharmaceutical has grown into a large-scale, high-tech pharmaceutical enterprise that integrates R&D and industrialization across multiple segments of the pharmaceutical value chain, including innovative drugs, generic drugs, specialty APIs, advanced dosage forms, and pharmaceutical packaging materials.

Technology shines with brilliance; Shisi Pharmaceutical remains committed to innovation-driven development, taking it as its mission to “research, develop, and produce more ‘Chinese medicines’ that are tailored to the genetic heritage and physical characteristics of the Chinese population.” In response to bottlenecks, challenges, and critical chokepoints in the biopharmaceutical industry, the company has undertaken original, pioneering scientific and technological breakthroughs, achieving breakthroughs in several areas—including the validation of ion channels as novel therapeutic targets and their subsequent drug development, the preparation of multilayer co-extruded infusion films, and aseptic manufacturing technology for dual-layer soft-bag liquid formulations—thus filling multiple domestic gaps and attaining internationally leading positions in key technologies. These achievements have resulted in numerous domestic “firsts” and “unicorns,” significantly boosting the company’s innovation momentum.

Smart innovation creates ultimate beauty. In recent years, Shisi Pharmaceutical has actively pursued digital transformation by introducing cutting-edge international technologies and equipping its facilities with fully automated, information-driven, and intelligent systems. This has enabled end-to-end digitalization of the entire product lifecycle, including an AI-assisted drug-screening platform that was recognized as an outstanding smart-manufacturing application by the Ministry of Industry and Information Technology. Moreover, the company’s globally most highly automated large-volume parenteral solution production line achieves full-process automation with “one-click” operation, seamlessly integrating intelligence with green practices and significantly enhancing the enterprise’s core competitiveness.

Shisi Pharmaceutical consistently upholds the corporate philosophy of “quality-driven care for the people, with integrity as the foundation,” fulfills its social responsibilities, and vigorously promotes technological innovation. Through digital transformation and upgrading, the company aligns its innovation ecosystem with the industrial value chain, focuses on emerging growth areas, and has forged a distinctive path of integrated development driven by technological innovation that is uniquely characteristic of Shisi Pharmaceutical.

According to reports, the “Industrial Strength” Outstanding Case Study of Corporate Chronicles and Archives is a practical initiative for promoting industrial culture and spirit, organized by the Industrial Culture Development Center of the Ministry of Industry and Information Technology and open to industrial enterprises nationwide. The initiative aims to further tap into corporate historical records and archives, carry forward the Chinese industrial spirit, showcase the image of China’s industry in the new era, and comprehensively and systematically highlight the admirable, trustworthy, and endearing qualities of industrial and information technology enterprises.

Keywords:

Shijiazhuang Sihua Pharmaceutical Group Ranked Among the Top 200 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region

Shijiazhuang Sihua Pharmaceutical Group’s Guolong Pharmaceutical Has Been Recognized as a Specialized, Sophisticated, and Novel “Little Giant” Enterprise.

Shijiazhuang Sihua Pharmaceutical Group Ranked Among the Top 200 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region

Shijiazhuang Sihua Pharmaceutical Group’s Guolong Pharmaceutical Has Been Recognized as a Specialized, Sophisticated, and Novel “Little Giant” Enterprise.